Suppr超能文献

在喂食胆固醇的大鼠进行降血脂药物治疗期间脂肪细胞胆固醇的蓄积

Accumulation of adipocyte cholesterol during hypolipidemic drug treatment in cholesterol-fed rats.

作者信息

Krause B R, Hartman A D

出版信息

Biochim Biophys Acta. 1982 Dec 13;713(3):485-93. doi: 10.1016/0005-2760(82)90308-3.

Abstract

An attempt was made to mobilize adipose tissue cholesterol independently of triacylglycerol by feeding cholesterol to intact Fischer 344 rats to 'load' adipocytes followed by hypolipidemic drug treatment in order to lower plasma cholesterol and, hence, adipocyte cholesterol. In this strain of rat, body weight and adipocyte sizes remain relatively constant after 1 year of age. Therefore, alterations in adipocyte cholesterol can be ascribed to factors other than cell size. Both oxandrolone and combined cholestyramine/clofibrate treatment caused significant reductions in plasma cholesterol in cholesterol-fed rats, but cholesterol concentrations in liver were reduced only by cholestyramine/clofibrate treatment. Oxandrolone enhanced the development of liver fatty liver in the cholesterol-fed rats, but cholestyramine/clofibrate significantly reduced liver triacylglycerol concentrations. Adipocyte cholesterol in the epididymal depot was significantly elevated, not lowered, in both concentrations. Adipocyte cholesterol in the epididymal depot was significantly elevated, not lowered, in both groups of drug-treated animals. Subcutaneous adipocytes from rats receiving drug treatment also contained more cholesterol, especially in rats given oxandrolone. Increments in adipocyte cholesterol were associated with decreases in the absolute amounts of apolipoproteins, A-I and A-IV, as measured by densitometric scanning of electrophoretic gels. Under the present experimental conditions, changes in plasma cholesterol scanning of electrophoretic gels. Under the present experimental conditions, changes in plasma cholesterol concentration did not adequately reflect the cholesterol content of either liver or adipose tissue.

摘要

通过给完整的Fischer 344大鼠喂食胆固醇以“加载”脂肪细胞,随后进行降血脂药物治疗以降低血浆胆固醇,从而降低脂肪细胞胆固醇,试图独立于三酰甘油来调动脂肪组织胆固醇。在这种品系的大鼠中,1岁以后体重和脂肪细胞大小保持相对恒定。因此,脂肪细胞胆固醇的变化可归因于细胞大小以外的因素。氧雄龙以及考来烯胺/氯贝丁酯联合治疗均使喂食胆固醇的大鼠血浆胆固醇显著降低,但仅考来烯胺/氯贝丁酯治疗降低了肝脏中的胆固醇浓度。氧雄龙加剧了喂食胆固醇大鼠的肝脏脂肪肝发展,但考来烯胺/氯贝丁酯显著降低了肝脏三酰甘油浓度。在两组接受药物治疗的动物中,附睾脂肪库中的脂肪细胞胆固醇均显著升高,而非降低。接受药物治疗的大鼠的皮下脂肪细胞也含有更多胆固醇,尤其是给予氧雄龙的大鼠。通过对电泳凝胶进行密度扫描测量,脂肪细胞胆固醇的增加与载脂蛋白A-I和A-IV绝对量的减少有关。在当前实验条件下,血浆胆固醇浓度的变化不能充分反映肝脏或脂肪组织的胆固醇含量。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验